{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:08:01Z","timestamp":1788869281891,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1136\/dtb.2024.000048","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:55:17Z","timestamp":1737957317000},"page":"22-26","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["What role for \u25bcgefapixant in chronic cough?"],"prefix":"10.1136","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct03449134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03449147","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04193202","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03449134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03449147","registry":"10.18810\/clinical-trials-gov"}],"member":"239","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"2026090804151603000_63.2.22.1","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0127-2021","article-title":"Chronic cough: new insights and future prospects","volume":"30","author":"Morice","year":"2021","journal-title":"Eur Respir Rev"},{"key":"2026090804151603000_63.2.22.2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219699"},{"key":"2026090804151603000_63.2.22.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02348-5"},{"key":"2026090804151603000_63.2.22.4","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2018.000014"},{"key":"2026090804151603000_63.2.22.5","unstructured":"European Medicines Agency . Assessment report Lyfnua [online], 2023. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lyfnua-epar-public-assessment-report_en.pdf [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.10.016"},{"key":"2026090804151603000_63.2.22.7","unstructured":"National Institute for Health and Care Excellence . Clinical Knowledge Summaries: cough [online]. 2023. Available: https:\/\/cks.nice.org.uk\/topics\/cough\/ [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1_suppl.54S"},{"key":"2026090804151603000_63.2.22.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-022-00370-w","article-title":"Cough hypersensitivity and chronic cough","volume":"8","author":"Chung","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2026090804151603000_63.2.22.10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2213-2600(13)70043-2","article-title":"Chronic cough as a neuropathic disorder","volume":"1","author":"Chung","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026090804151603000_63.2.22.11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur Respir J"},{"key":"2026090804151603000_63.2.22.12","unstructured":"Lyfnua 45 mg film-coated tablets . Summary of Product Characteristics, GB. Merck Sharp & Dohme (UK) Limited; December 2023."},{"key":"2026090804151603000_63.2.22.13","unstructured":"European Medicines Agency . Lyfnua (gefapixant) [online]. 2023. Available: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lyfnua-epar-medicine-overview_en.pdf [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00439-2019","article-title":"The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study","volume":"54","author":"Morice","year":"2019","journal-title":"Eur Respir J"},{"key":"2026090804151603000_63.2.22.15","unstructured":"Merck Sharp & Dohme LLC . A study of gefapixant (MK-7264) in adult participants with chronic cough (MK-7264-027) [online]. 2021. Available: https:\/\/clinicaltrials.gov\/study\/NCT03449134 [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.16","unstructured":"Merck Sharp & Dohme LLC . A study of gefapixant (MK-7264) in adult participants with chronic cough (MK-7264-030) [online]. 2016. Available: https:\/\/clinicaltrials.gov\/study\/NCT03449147 [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.17","unstructured":"Food and Drug Administration . Final summary minutes of the Pulmonary-Allergy Drugs Advisory Committee meeting November 17, 2023 [online]. 2023. Available: https:\/\/www.fda.gov\/media\/176352\/download [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.12.519","article-title":"Defining Minimal Clinically Important Differences (MCID) in Chronic Cough: Analyses of Objective Cough Counts from a Phase 2 Randomized Controlled Trial","volume":"143","author":"Nguyen","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"2026090804151603000_63.2.22.19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00408-023-00606-w","article-title":"The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"key":"2026090804151603000_63.2.22.20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2023.18035","article-title":"Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis","volume":"330","author":"Kum","year":"2023","journal-title":"JAMA"},{"key":"2026090804151603000_63.2.22.21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jama.2023.18508","article-title":"Gefapixant for Refractory or Unexplained Chronic Cough?","volume":"330","author":"Irwin","year":"2023","journal-title":"JAMA"},{"key":"2026090804151603000_63.2.22.22","unstructured":"Medicines and Healthcare products Regulatory Agency . Public Assessment Report National Procedure Lyfnua 46 mg film-coated tablets: gefapixant citrate [online]. 2023. Available: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/b7d1d94a2ef609c09b1b0c48de1811fef5ea74eb [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.23","unstructured":"Food and Drug Administration . Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting [online]. 2023. Available: https:\/\/www.fda.gov\/media\/176353\/download [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.24","unstructured":"National Institute for Health and Care Excellence . Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal): technology appraisal guidance [online]. 2024. Available: www.nice.org.uk\/guidance\/ta969 [Accessed 2 Jan 2025]."},{"key":"2026090804151603000_63.2.22.25","unstructured":"Jiang YT . Personal communication. 2024."},{"key":"2026090804151603000_63.2.22.26","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.339"},{"key":"2026090804151603000_63.2.22.27","doi-asserted-by":"crossref","unstructured":"Raj AA , Pavord DI , Birring SS . Clinical cough IV:what is the minimal important difference for the Leicester Cough Questionnaire? Handb Exp Pharmacol 2009;311\u201320. doi:10.1007\/978-3-540-79842-2_16","DOI":"10.1007\/978-3-540-79842-2_16"},{"key":"2026090804151603000_63.2.22.28","doi-asserted-by":"crossref","first-page":"17534666221099737","DOI":"10.1177\/17534666221099737","article-title":"Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough","volume":"16","author":"Nguyen","year":"2022","journal-title":"Ther Adv Respir Dis"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2024.000048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:15:30Z","timestamp":1788866130000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2024.000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/dtb.2024.000048"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2024.000048","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}